Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLM033
MIFTS: 58

Pulmonary Embolism

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Embolism

About this section

MalaCards integrated aliases for Pulmonary Embolism:

Name: Pulmonary Embolism 12 29 54 6 42 44 15 62 17 70 32
Pulmonary Artery Embolism 12
Pulmonary Embolus 12
Pulmonary Emboli 15

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9477
MeSH 44 D011655
NCIt 50 C50713
SNOMED-CT 67 194882001
ICD10 32 I26 I26.0 I26.9
UMLS 70 C0034065
Sources

Summaries for Pulmonary Embolism

About this section
MedlinePlus : 42 What is a pulmonary embolism (PE)? A pulmonary embolism (PE) is a sudden blockage in a lung artery. It usually happens when a blood clot breaks loose and travels through the bloodstream to the lungs. PE is a serious condition that can cause Permanent damage to the lungs Low oxygen levels in your blood Damage to other organs in your body from not getting enough oxygen PE can be life-threatening, especially if a clot is large, or if there are many clots. What causes a pulmonary embolism (PE)? The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung. Who is at risk for a pulmonary embolism (PE)? Anyone can get a pulmonary embolism (PE), but certain things can raise your risk of PE: Having surgery, especially joint replacement surgery Certain medical conditions, including Cancers Heart diseases Lung diseases A broken hip or leg bone or other trauma Hormone-based medicines, such as birth control pills or hormone replacement therapy Pregnancy and childbirth. The risk is highest for about six weeks after childbirth. Not moving for long periods, such as being on bed rest, having a cast, or taking a long plane flight Age. Your risk increases as you get older, especially after age 40. Family history and genetics. Certain genetic changes that can increase your risk of blood clots and PE. Obesity What are the symptoms of a pulmonary embolism (PE)? Half the people who have pulmonary embolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. How is a pulmonary embolism (PE) diagnosed? It can be difficult to diagnose PE. To make a diagnosis, your health care provider will Take your medical history, including asking about your symptoms and risk factors for PE Do a physical exam Run some tests, including various imaging tests and possibly some blood tests What are the treatments for a pulmonary embolism (PE)? If you have PE, you need medical treatment right away. The goal of treatment is to break up clots and help keep other clots from forming. Treatment options include medicines and procedures. Medicines Anticoagulants, or blood thinners, keep blood clots from getting larger and stop new clots from forming. You might get them as an injection, a pill, or through an I.V. (intravenous). They can cause bleeding, especially if you are taking other medicines that also thin your blood, such as aspirin. Thrombolytics are medicines to dissolve blood clots. You may get them if you have large clots that cause severe symptoms or other serious complications. Thrombolytics can cause sudden bleeding, so they are used if your PE is serious and may be life-threatening. Procedures Catheter-assisted thrombus removal uses a flexible tube to reach a blood clot in your lung. Your health care provider can insert a tool in the tube to break up the clot or to deliver medicine through the tube. Usually you will get medicine to put you to sleep for this procedure. A vena cava filter may be used in some people who cannot take blood thinners. Your health care provider inserts a filter inside a large vein called the vena cava. The filter catches blood clots before they travel to the lungs, which prevents pulmonary embolism. But the filter does not stop new blood clots from forming. Can pulmonary embolism (PE) be prevented? Preventing new blood clots can prevent PE. Prevention may include Continuing to take blood thinners. It's also important to get regular checkups with your provider, to make sure that the dosage of your medicines is working to prevent blood clots but not causing bleeding. Heart-healthy lifestyle changes, such as heart-healthy eating, exercise, and, if you smoke, quitting smoking Using compression stockings to prevent deep vein thrombosis (DVT) Moving your legs when sitting for long periods of time (such as on long trips) Moving around as soon as possible after surgery or being confined to a bed NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Embolism, also known as pulmonary artery embolism, is related to chronic thromboembolic pulmonary hypertension and pulmonary embolism and infarction, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Pulmonary Embolism is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Acetylcysteine and Streptokinase have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and spinal cord, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An artery disease characterized by a blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body, e.g. a blood clot.

PubMed Health : 62 About pulmonary embolism: Pulmonary embolism (PULL-mun-ary EM-bo-lizm), or PE, is a sudden blockage in a lung artery. The blockage usually is caused by a blood clot that travels to the lung from a vein in the leg. A clot that forms in one part of the body and travels in the bloodstream to another part of the body is called an embolus (EM-bo-lus). PE is a serious condition that can:

Wikipedia : 73 Pulmonary embolism (PE) is a blockage of an artery in the lungs by a substance that has moved from... more...

Sources

Related Diseases for Pulmonary Embolism

About this section

Diseases related to Pulmonary Embolism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1170)
# Related Disease Score Top Affiliating Genes
1 chronic thromboembolic pulmonary hypertension 32.8 NPPB FGB CRP
2 pulmonary embolism and infarction 32.7 F3 F2
3 prothrombin thrombophilia 32.5 MTHFR F2 F13A1
4 puerperal pulmonary embolism 32.4 SERPINC1 F10 APOH
5 respiratory failure 32.2 NPPB F3 F2 CRP ALB
6 cardiogenic shock 32.0 PLAT NPPB
7 cardiac arrest 31.9 TNNT2 TNNI3 NPPB ALB
8 antithrombin iii deficiency 31.9 SERPINC1 MTHFR F5 F2 F10 APOH
9 protein c deficiency 31.9 SERPINE1 SERPINC1 MTHFR F9 F5 F2
10 essential thrombocythemia 31.8 VWF SERPINE1 SERPINC1 MTHFR F3 F2
11 thrombophilia due to thrombin defect 31.7 VWF SERPINE1 SERPINC1 PLAT MTHFR F5
12 protein s deficiency 31.6 SERPINC1 MTHFR F5 F3 F2 F10
13 pulmonary hypertension 31.5 VWF SERPINE1 SERPINC1 PLAT NPPB F3
14 acute cor pulmonale 31.5 PLAT NPPB F3 F2 CRP
15 covid-19 31.4 VWF TNNI3 NPPB F3
16 heparin-induced thrombocytopenia 31.3 SERPINC1 F3 F10
17 tricuspid valve insufficiency 31.3 TNNI3 NPPB F3 F2 CRP ALB
18 sleep apnea 31.3 SERPINE1 NPPB CRP ALB
19 thrombophilia due to activated protein c resistance 31.2 VWF SERPINE1 SERPINC1 MTHFR F5 F3
20 varicose veins 31.2 VWF SERPINC1 PLAT MTHFR F5 F2
21 pulmonary edema 31.1 TNNT2 TNNI3 SERPINC1 NPPB F2 CRP
22 vascular disease 31.1 VWF SERPINE1 SERPINC1 PLAT NPPB MTHFR
23 congestive heart failure 31.1 TNNT2 TNNI3 NPPB FABP3 CRP ALB
24 inferior myocardial infarction 31.0 TNNI3 PLAT NPPB
25 post-thrombotic syndrome 31.0 SERPINE1 SERPINC1 F5 F3 F2
26 toxic shock syndrome 31.0 SERPINC1 F3 CRP
27 endocarditis 31.0 TNNI3 SERPINE1 SERPINC1 PLAT F2 CRP
28 pericardial effusion 31.0 TNNI3 NPPB F3 F2 CRP ALB
29 infective endocarditis 31.0 TNNT2 TNNI3 SERPINE1 F2 CRP APOH
30 hemopericardium 30.9 TNNI3 F9 F3 F2 CRP
31 pericarditis 30.9 TNNT2 TNNI3 NPPB CRP ALB
32 end stage renal disease 30.9 NPPB MTHFR CRP ALB
33 may-thurner syndrome 30.9 F5 APOH
34 left bundle branch hemiblock 30.8 TNNT2 TNNI3 NPPB CRP
35 angina pectoris 30.8 TNNI3 PLAT NPPB F3 CRP
36 compartment syndrome 30.8 SERPINC1 F3 F2 CRP ALB
37 lemierre's syndrome 30.8 MTHFR F3 F2 CRP
38 bronchopneumonia 30.8 F3 CRP ALB
39 deficiency anemia 30.8 SERPINC1 F5 F2 CRP ALB
40 venous insufficiency 30.8 VWF SERPINE1 PLAT MTHFR F5 F2
41 pleural empyema 30.8 F2 CRP ALB
42 patent ductus arteriosus 1 30.7 NPPB CRP ALB
43 aortic aneurysm, familial abdominal, 1 30.7 SERPINE1 SERPINC1 CRP ALB
44 acute pulmonary heart disease 30.7 PLAT NPPB F3 F2
45 chronic venous insufficiency 30.7 SERPINE1 PLAT MTHFR F2 CRP
46 cellulitis 30.7 F3 F2 CRP ALB
47 sticky platelet syndrome 30.7 SERPINE1 SERPINC1 F5
48 thoracic outlet syndrome 30.7 SERPINC1 F2
49 esophageal varix 30.6 SERPINC1 F3 F2 ALB
50 anuria 30.6 F3 F2 CRP ALB

Graphical network of the top 20 diseases related to Pulmonary Embolism:



Diseases related to Pulmonary Embolism
Sources

Symptoms & Phenotypes for Pulmonary Embolism

About this section

UMLS symptoms related to Pulmonary Embolism:


hemoptysis; snoring; coughing

MGI Mouse Phenotypes related to Pulmonary Embolism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 ALB CRP F10 F13A1 F2 F3
2 homeostasis/metabolism MP:0005376 10.11 ALB APOH CRP F10 F13A1 F2
3 mortality/aging MP:0010768 9.89 ALB APOH F10 F13A1 F2 F3
4 muscle MP:0005369 9.23 ALB F2 F3 FABP3 PLAT SERPINC1
Sources

Drugs & Therapeutics for Pulmonary Embolism

About this section

PubMed Health treatment related to Pulmonary Embolism: 62

Pulmonary embolism (PE) is treated with medicines, procedures, and other therapies . The main goals of treating PE are to stop the blood clot from getting bigger and keep new clots from forming. Treatment may include medicines to thin the blood and slow its ability to clot. If your symptoms are life threatening, your doctor may give you medicine to quickly dissolve the clot. Rarely, your doctor may use surgery or another procedure to remove the clot.

Drugs for Pulmonary Embolism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Streptokinase Approved, Investigational Phase 4 9002-01-1
3
Warfarin Approved Phase 4 81-81-2 54678486 6691
4
Vitamin K1 Approved, Investigational Phase 4 84-80-0 5284607
5
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
6
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
9
Phenindione Approved, Investigational Phase 4 83-12-5 4760
10
fluindione Approved, Investigational Phase 4 957-56-2
11
Nadroparin Approved, Investigational Phase 4
12
Tenecteplase Approved Phase 4 191588-94-0
13
Dalteparin Approved Phase 4 9005-49-6
14
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
15
Enoxaparin Approved Phase 4 9005-49-6 772
16
Apixaban Approved Phase 4 503612-47-3 10182969
17
tannic acid Approved Phase 4 1401-55-4
18
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
19
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
20 Menaquinone Investigational Phase 4 1182-68-9
21
Tezosentan Investigational Phase 4 180384-57-0
22
Coumarin Experimental Phase 4 91-64-5 323
23
Monteplase Investigational Phase 4 156616-23-8
24
Dabigatran Investigational Phase 4 211914-51-1
25 Respiratory System Agents Phase 4
26 Pharmaceutical Solutions Phase 4
27 Expectorants Phase 4
28 Anti-Infective Agents Phase 4
29 Antioxidants Phase 4
30 Antiviral Agents Phase 4
31 N-monoacetylcystine Phase 4
32 Protective Agents Phase 4
33 Nutrients Phase 4
34 Trace Elements Phase 4
35 Micronutrients Phase 4
36 Vitamins Phase 4
37 Vasodilator Agents Phase 4
38 Vitamin K Phase 4
39 naphthoquinone Phase 4
40 Antihypertensive Agents Phase 4
41 Anti-Bacterial Agents Phase 4
42 diuretics Phase 4
43 Sodium Potassium Chloride Symporter Inhibitors Phase 4
44 Antidotes Phase 4
45 Amoxicillin-Potassium Clavulanate Combination Phase 4
46 Clavulanic Acids Phase 4
47 beta-Lactamase Inhibitors Phase 4
48 Antivitamins K Phase 4
49 Liver Extracts Phase 4
50 Plasminogen Phase 4

Interventional clinical trials:

(show top 50) (show all 552)
# Name Status NCT ID Phase Drugs
1 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
2 Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized，Multi-Center，Controlled Trial Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
3 Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism Unknown status NCT00214929 Phase 4
4 A Prospective Randomised Controlled Study to Evaluate Outcomes of the Treatment With Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism Undergoing Endovascular Mechanical Fragmentation and Thrombolytic Therapy Unknown status NCT02979561 Phase 4 Dabigatran Etexilate;Warfarin
5 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism: AYKAN Trial Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
6 The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism. Unknown status NCT03129555 Phase 4 Dabigatran Etexilate Oral Capsule;Rivaroxaban Oral Tablet;Edoxaban Oral Tablet;Apixaban Oral Tablet
7 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) Unknown status NCT01252420 Phase 4 Enoxaparin
8 N-acetylcysteine, Sodium Bicarbonate and Normal Saline Alone Prophylaxis for Spiral Computed Tomography Pulmonary Angiography in the Emergency Department on Suspicion of Pulmonary Emboli: A Randomized Controlled Trial Completed NCT02483143 Phase 4 NAC;NaHCO3;Normal Saline
9 Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00968929 Phase 4 Recombinant Streptokinase;Urokinase
10 PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study Completed NCT00457158 Phase 4
11 Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
12 Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism Completed NCT01014156 Phase 4 epoprostenol
13 Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism Completed NCT00711308 Phase 4 tinzaparin;acenocoumarol
14 Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain Completed NCT01067456 Phase 4
15 Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial) Completed NCT02066662 Phase 4 Rivaroxaban or Marcumar
16 Objective Assessment of Pulmonary Embolism Can be Deferred Without Increased Risk Completed NCT00381511 Phase 4 low molecular weight heparin
17 A Non-Randomized Prospective Study of IVC Filter Retrieval Completed NCT00196118 Phase 4
18 Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive Completed NCT02531581 Phase 4 Furosemide;NaCl 9% isotonic
19 Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism: a Prospective Outcome Study. Completed NCT01134068 Phase 4
20 Chemoprophylaxis Plus Early Ambulation Prevent Chinese Thoracic Surgery Patients From Pulmonary Embolism Completed NCT03862755 Phase 4 Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
21 Pharmacokinetic/Pharmacodynamic Study of Monteplase ("Cleactor") in Acute Pulmonary Embolism Completed NCT00442234 Phase 4 Monteplase
22 Detection of Pulmonary Embolism Comparing Isovue-370 and Visipaque 320 Using 64-Slice Multi-Detector Computed Tomographic Angiography Completed NCT00351754 Phase 4 Isovue
23 The Cordis Protection From Pulmonary Embolism With the Permanent OptEaseâ„¢ Filter - A Post Marketing Surveillance Study (PROOF Study) Completed NCT00233740 Phase 4
24 Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon Completed NCT00586287 Phase 4 Phenprocoumon
25 Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00799968 Phase 4 Urokinase;Urokinase
26 Efficacy and Safety Evaluation of Low Dosage of Recombinant Tissue Plasminogen Activator (rt-PA) in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00781378 Phase 4 rt-PA;rt-PA
27 Efficacy and Safety of Body Weight Adjusted Nadroparin vs Standard Unfractionated Heparin for the Initial Treatment of Pulmonary Thromboembolism：a Multi-Centre, Randomised Controlled Trial in China Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
28 Study of the OPTtimum Duration of Acoustic Pulse ThromboLYSis ProcEdure in the Treatment of Acute Submassive Pulmonary Embolism Completed NCT02396758 Phase 4
29 MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department Completed NCT02584660 Phase 4 Rivaroxaban;Standard-of-care
30 Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability Completed NCT02132689 Phase 4 Actilyse (Thrombolytic therapy);Heparine (Standard anticoagulation therapy)
31 Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism Completed NCT00365950 Phase 4 Duration of anticoagulation;Warfarin duration
32 Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention Completed NCT00187408 Phase 4 Low Molecular Weight Heparin (dalteparin)
33 Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
34 Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial Completed NCT01104337 Phase 4 paracetamol;paracetamol;Placebo
35 D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized "Prolong" Study Completed NCT00264277 Phase 4 Vitamin K antagonist (Coumarin anticoagulants)
36 Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid Completed NCT00603317 Phase 4 Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo;Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid
37 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
38 Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist's Dosing Completed NCT00511173 Phase 4
39 Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test in Patients at Extremely High Risk of Postoperative Venous Thromboembolism. Recruiting NCT04710732 Phase 4 Standard Enoxaparin 40 mg once-daily before randomization;Standard Enoxaparin 40 mg once-daily after randomization;Escalated Enoxaparin 30 mg twice-daily after randomization
40 Anti-Xa Concentrations With Continuous Intravenous Infusion and Subcutaneous Administration of Enoxaparin After Coronary Artery Bypass Grafting: Randomized Clinical Trial Recruiting NCT02474212 Phase 4 Enoxaparin
41 Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement: Balancing Safety and Effectiveness Recruiting NCT02810704 Phase 4 Enteric Coated Aspirin;Warfarin;Rivaroxaban
42 Peripheral Low Dose Systemic Thrombolysis Versus Catheter Directed Acoustic Pulse Thrombolysis for Treatment of Submassive Pulmonary Embolism Recruiting NCT03581877 Phase 4 Alteplase
43 Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial Recruiting NCT04263038 Phase 4 Rivaroxaban;Placebo
44 Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer Recruiting NCT04724460 Phase 4 Long DOAC;Short DOAC
45 Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses Recruiting NCT01828697 Phase 4 Low dose nadroparin;Intermediate dose nadroparin;Low dose enoxaparin;Intermediate dose enoxaparin;Low dose dalteparin;Intermediate dose dalteparin;Fixed low dose tinzaparin;Intermediate dose tinzaparin
46 Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Recruiting NCT04373707 Phase 4 Enoxaparin;Enoxaparin
47 Low-Dose Tenecteplase in Covid-19 Patients With Acture Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial Active, not recruiting NCT04558125 Phase 4 TNKase
48 Thromboprophylaxis With Fondaparinux of Deep Vein Thrombosis and Pulmonary Embolism in the Acutely-ill Medical Inpatients With Thrombocytopenia Active, not recruiting NCT01727401 Phase 4 Fondaparinux
49 Randomized Controlled Trial of Extended-Duration Low-Dose Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Not yet recruiting NCT04168203 Phase 4 Apixaban 2.5 MG;Placebo oral tablet
50 A Randomized Trial of Ultrasound-facilitated, Catheter-directed, Low-dose Fibrinolysis Versus Anticoagulation for Acute Intermediate-high Risk Pulmonary Embolism: The Higher-risk Pulmonary Embolism Thrombolysis Study Not yet recruiting NCT04790370 Phase 4 Anticoagulation with heparin

Search NIH Clinical Center for Pulmonary Embolism

Inferred drug relations via UMLS 70 / NDF-RT 51 :


alteplase
anisindione
Anistreplase
apixaban
Dalteparin
Dalteparin Sodium
danaparoid
Danaparoid sodium
Dicumarol
Enoxaparin
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Papaverine
Papaverine Hydrochloride
Phenprocoumon
rivaroxaban
Streptokinase
tinzaparin
Tinzaparin sodium
Urokinase
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: pulmonary embolism

Sources

Genetic Tests for Pulmonary Embolism

About this section

Genetic tests related to Pulmonary Embolism:

# Genetic test Affiliating Genes
1 Pulmonary Embolism (disease) 29
Sources

Anatomical Context for Pulmonary Embolism

About this section

MalaCards organs/tissues related to Pulmonary Embolism:

40
Lung, Heart, Spinal Cord, Prostate, Endothelial, Neutrophil, Liver
Sources

Publications for Pulmonary Embolism

About this section

Articles related to Pulmonary Embolism:

(show top 50) (show all 31946)
# Title Authors PMID Year
1
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. 61 42
33726018 2021
2
Incidence of pulmonary embolism in patients with non-invasive respiratory support during COVID-19 outbreak. 61 42
33581510 2021
3
Pulmonary Embolism Does Not Have an Unusually High Incidence Among Hospitalized COVID19 Patients. 61 42
33689493 2021
4
Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. 61 54
20513806 2010
5
Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. 61 54
20007142 2010
6
Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. 54 61
20447541 2010
7
Etanercept and venous thromboembolism: a case series. 61 54
20157435 2010
8
A serious drug interaction leading to spontaneous total hyphema. 61 54
20393256 2010
9
Clinical usefulness of prothrombin fragment 1+2 in patients with suspected pulmonary embolism. 61 54
19394681 2010
10
[High-risk factors and clinical pathological analysis in 21 cases of fatal pulmonary embolism]. 61 54
20019774 2009
11
Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. 54 61
19525265 2009
12
Thrombophilia-related genetic variations in patients with pulmonary embolism in the main teaching hospital in Jordan. 61 54
19618008 2009
13
Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome. 54 61
20040816 2009
14
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 61 54
19247590 2009
15
Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. 54 61
19087222 2009
16
N-terminal pro-B-type natriuretic peptide predicts the burden of pulmonary embolism. 54 61
19214022 2009
17
Thrombo-embolic occlusion of the left anterior descending coronary artery complicating left atrial radiofrequency ablation. 61 54
18988653 2009
18
[Heparin-induced thrombocythopenia in a patient with massive pulmonary embolism and dilated cardiomyopathy, successfuly treated with fondaparinux - a case report]. 54 61
19169978 2008
19
B-type natriuretic peptide in acute pulmonary embolism. 54 61
18706401 2008
20
Natriuretic peptides in acute pulmonary embolism: a systematic review. 61 54
18626627 2008
21
Mechanisms of the factor V Leiden paradox. 61 54
18617648 2008
22
[Massive pulmonary embolism]. 61 54
18775637 2008
23
[Oral contraceptives use increases venous thromboembolic risk even for minor surgical procedure - a case report]. 61 54
19006032 2008
24
Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. 61 54
18664972 2008
25
B-type natriuretic peptide as an indicator of right ventricular dysfunction in acute pulmonary embolism. 54 61
17537186 2008
26
[Massive pulmonary embolism treated with a reduced dose of alteplase in a patient with acute renal failure]. 54 61
18803142 2008
27
Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism. 61 54
18657661 2008
28
Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. 54 61
18556626 2008
29
Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. 61 54
18495689 2008
30
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. 54 61
18256058 2008
31
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors. 61 54
18041082 2008
32
HyBeacon probes for rapid DNA sequence detection and allele discrimination. 54 61
18695966 2008
33
Recurrent thrombembolic risk in patients with multiple thrombophilic disorders. 61 54
19366087 2008
34
Correlation between cardiac biomarkers and right ventricular enlargement on chest CT in non massive pulmonary embolism. 61 54
17716710 2008
35
Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. 61 54
18158473 2008
36
Epidural hematoma following tissue plasminogen activator (tPA) therapy for pulmonary embolism in a pediatric patient with stage IV Burkitt's lymphoma: a case report. 61 54
17854866 2008
37
[The efficacy of alteplase in pulmonary embolism treatment]. 54 61
18833155 2008
38
Prognostic value of brain natriuretic peptide in acute pulmonary embolism. 54 61
18721456 2008
39
[Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients]. 61 54
17874721 2007
40
Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. 61 54
17507005 2007
41
Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism. 54 61
17513552 2007
42
Tenecteplase to treat pulmonary embolism in the emergency department. 61 54
17221330 2007
43
Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. 54 61
16814410 2007
44
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 54 61
17345160 2007
45
Spotlight on reteplase in thrombotic occlusive disorders. 61 54
17263591 2007
46
[Value of plasma BNP levels as a prognostic marker in lung and heart disorders]. 54 61
17978918 2007
47
Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. 54 61
17127709 2007
48
Heart-type fatty acid-binding proteins (H-FABP): a reliable tool for initial risk stratification of pulmonary embolism? 61 54
17208938 2007
49
Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. 54 61
17145624 2007
50
Massive pulmonary embolism secondary to anticardiolipin antibody syndrome. 54 61
17256569 2007
Sources

Variations for Pulmonary Embolism

About this section

ClinVar genetic disease variations for Pulmonary Embolism:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PLAT NM_000930.5(PLAT):c.826C>T (p.Pro276Ser) SNV Uncertain significance 627396 rs367827951 GRCh37: 8:42039518-42039518
GRCh38: 8:42182000-42182000
Sources

Expression for Pulmonary Embolism

About this section
Search GEO for disease gene expression data for Pulmonary Embolism.
Sources

Pathways for Pulmonary Embolism

About this section

Pathways related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.08 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB
2
Collagen chain trimerization 65
Show member pathways
 12.59 SERPINC1 FGB F9 F5 F3 F2
3
Folate Metabolism 1
Show member pathways
 12.13 SERPINE1 PLAT MTHFR F2 CRP ALB
4
Formation of Fibrin Clot (Clotting Cascade) 65
Show member pathways
 11.94 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB
5
Integrin alphaIIb beta3 signaling 65
Show member pathways
 11.64 VWF FGB F2
6
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.61 TNNT2 TNNI3 FABP3
7
Complement and coagulation cascades 36 1
11.56 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB
8
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
11.32 VWF FGB F2
9
Warfarin Pathway, Pharmacodynamics 60
10.76 F9 F2 F10
10
Dissolution of Fibrin Clot 65
10.66 SERPINF2 SERPINE1 PLAT
Sources

GO Terms for Pulmonary Embolism

About this section

Cellular components related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.16 VWF SERPINF2 SERPINE1 SERPINC1 PLAT NPPB
2 extracellular exosome GO:0070062 10.14 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB
3 extracellular space GO:0005615 9.86 VWF SERPINF2 SERPINE1 SERPINC1 PLAT NPPB
4 endoplasmic reticulum lumen GO:0005788 9.85 SERPINC1 F9 F5 F2 F10 ALB
5 blood microparticle GO:0072562 9.8 SERPINF2 SERPINC1 FGB F2 F13A1 ALB
6 platelet alpha granule lumen GO:0031093 9.7 VWF SERPINF2 SERPINE1 FGB F5 F13A1
7 platelet alpha granule GO:0031091 9.61 VWF FGB F5
8 troponin complex GO:0005861 9.52 TNNT2 TNNI3
9 fibrinogen complex GO:0005577 9.51 SERPINF2 FGB
10 cardiac myofibril GO:0097512 9.49 TNNT2 TNNI3
11 cardiac Troponin complex GO:1990584 9.48 TNNT2 TNNI3
12 intrinsic component of external side of plasma membrane GO:0031233 9.46 F3 F10
13 collagen-containing extracellular matrix GO:0062023 9.36 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB

Biological processes related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.85 SERPINC1 F5 F2 ALB
2 ER to Golgi vesicle-mediated transport GO:0006888 9.84 F9 F5 F2 F10
3 platelet degranulation GO:0002576 9.76 VWF SERPINF2 SERPINE1 FGB F5 F13A1
4 blood coagulation, intrinsic pathway GO:0007597 9.67 VWF F9 F2 APOH
5 acute-phase response GO:0006953 9.65 SERPINF2 F2 CRP
6 fibrinolysis GO:0042730 9.65 SERPINF2 SERPINE1 PLAT FGB F2
7 blood coagulation GO:0007596 9.65 VWF SERPINC1 PLAT FGB F9 F5
8 positive regulation of blood coagulation GO:0030194 9.63 SERPINE1 F2 APOH
9 negative regulation of fibrinolysis GO:0051918 9.62 SERPINF2 SERPINE1 F2 APOH
10 regulation of blood coagulation GO:0030193 9.61 SERPINC1 F2 APOH
11 plasminogen activation GO:0031639 9.58 PLAT FGB APOH
12 negative regulation of blood coagulation GO:0030195 9.57 SERPINE1 APOH
13 negative regulation of ATPase activity GO:0032780 9.56 TNNT2 TNNI3
14 blood coagulation, fibrin clot formation GO:0072378 9.52 FGB F13A1
15 negative regulation of plasminogen activation GO:0010757 9.51 SERPINF2 SERPINE1
16 blood coagulation, extrinsic pathway GO:0007598 9.49 F3 F10
17 hemostasis GO:0007599 9.28 VWF SERPINC1 FGB F9 F5 F3

Molecular functions related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 VWF TNNT2 TNNI3 SERPINF2 SERPINE1 SERPINC1
2 signaling receptor binding GO:0005102 9.72 SERPINE1 PLAT NPPB FGB F2
3 serine-type peptidase activity GO:0008236 9.56 PLAT F9 F2 F10
4 serine-type endopeptidase activity GO:0004252 9.35 PLAT F9 F3 F2 F10
5 troponin C binding GO:0030172 9.16 TNNT2 TNNI3
6 protease binding GO:0002020 9.02 VWF SERPINF2 SERPINE1 SERPINC1 F3
Sources

Sources for Pulmonary Embolism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....